Genelux Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas D. Zindrick
- Full Time Employees
- 26
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2625 Townsgate Road Westlake Village CA United States of America 91361
- IPO Date
- Jan 26, 2023
- CIK
- 0001231457
- Website
- genelux.com
- Similar Companies
- Business
- Genelux Corporation stands as an advanced clinical-stage biopharmaceutical entity, dedicated to pioneering innovative oncolytic viral immunotherapies for individuals battling aggressive and hard-to-treat solid tumor cancers. The company's lead therapeutic, Olvi-Vec (olvimulogene nanivacirepvec), represents a distinctively modified vaccinia virus engineered to not only directly target and destroy cancer cells but also to activate a specific immune response against tumors, fundamentally shifting the tumor microenvironment from an immunosuppressive to an immunoreactive state. This mechanism is designed to potentially restore sensitivity to platinum-based chemotherapies. Olvi-Vec is presently in a pivotal Phase 3 registrational study for platinum-resistant/refractory ovarian cancer, a program that has garnered FDA Fast Track Designation, with results from this trial expected in the latter half of 2026. Furthermore, Olvi-Vec is advancing through Phase 2 investigations for recurrent non-small cell lung cancer and Phase 1b/2 studies for small cell lung cancer, having demonstrated encouraging initial findings. In addition to its primary program, Genelux is developing V2ACT Immunotherapy, a personalized anti-cancer approach forged through a joint venture, which has received FDA clearance for an Investigational New Drug application to initiate a Phase 1/2a study in pancreatic cancer. An animal health candidate, V-VET1, also features in its portfolio, licensed for treating canine cancers. The company leverages its proprietary CHOICE™ discovery platform as the foundation for generating diverse oncolytic vaccinia virus product candidates. Founded in 2001, Genelux maintains its principal operations in Westlake Village, California.
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
Genelux Corporation Announces Proposed Public Offering of Common Stock
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer